{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:21:10Z","timestamp":1792023670032,"version":"4.4.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.arbres.2017.03.018","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T05:15:23Z","timestamp":1493874923000},"page":"324-335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":297,"title":["Gu\u00eda espa\u00f1ola de la enfermedad pulmonar obstructiva cr\u00f3nica (GesEPOC) 2017. Tratamiento farmacol\u00f3gico en fase estable"],"prefix":"10.1016","volume":"53","author":[{"given":"Marc","family":"Miravitlles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Soler-Catalu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Almagro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Quintano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Trigueros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja G.","family":"Cos\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Antonio Riesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Simonet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rigau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan B.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ancochea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2017.03.018_bib0005","doi-asserted-by":"crossref","unstructured":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545-602.","DOI":"10.1016\/S0140-6736(16)31678-6"},{"key":"10.1016\/j.arbres.2017.03.018_bib0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.arbres.2012.04.001","article-title":"Pharmacological treatment of stable COPD","volume":"48","author":"Miravitlles","year":"2012","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2017.03.018_bib0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5507\/bp.2013.039","article-title":"Chronic obstructive pulmonary disease: Official diagnosis and treatment guidelines biomed of the Czech Pneumological and Phthisiological society: A novel phenotypic approach to COPD with patient oriented care","volume":"157","author":"Koblizek","year":"2013","journal-title":"Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.arbres.2017.03.018_bib0020","article-title":"Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: The Finnish guidelines. Guidelines of the Finnish Medical Society Duodecim and the Finnish Respiratory Society","author":"Kankaanranta","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.arbres.2017.03.018_bib0025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2147\/COPD.S124482","article-title":"Clinical audit of COPD in outpatient respiratory clinics in Spain: The EPOCONSUL study","volume":"12","author":"Calle","year":"2017","journal-title":"Int J Chron Obstruct Pulm Dis"},{"key":"10.1016\/j.arbres.2017.03.018_bib0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.arbres.2012.12.001","article-title":"Calidad y fuerza: el sistema GRADE para la formulaci\u00f3n de recomendaciones en las gu\u00edas de pr\u00e1ctica cl\u00ednica","volume":"49","author":"Alonso-Coello","year":"2013","journal-title":"Arch Bronconeumol"},{"issue":"ext 1","key":"10.1016\/j.arbres.2017.03.018_bib0035","first-page":"4","article-title":"Gu\u00eda de Pr\u00e1ctica Cl\u00ednica para el Diagn\u00f3stico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Cr\u00f3nica (EPOC) - Gu\u00eda Espa\u00f1ola de la EPOC (GesEPOC). Versi\u00f3n 2017.","volume":"53","year":"2017","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2017.03.018_bib0040","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1378\/chest.06-1349","article-title":"Spirometric criteria for airway obstruction: Use percentage of FEV1\/FVC ratio below the fifth percentile, not<70%","volume":"131","author":"Hansen","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2017.03.018_bib0045","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.arbres.2017.02.001","article-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary","volume":"53","author":"Vogelmeier","year":"2017","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.arbres.2017.03.018_bib0050","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S2213-2600(15)00157-5","article-title":"Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: A pooled analysis of individual patient data","volume":"3","author":"Soriano","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0055","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021322","article-title":"The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease","volume":"350","author":"Celli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0060","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.rmed.2008.12.005","article-title":"Severe exacerbations and BODE index: Two independent risk factors for death in male COPD patients","volume":"103","author":"Soler-Catalu\u00f1a","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0065","doi-asserted-by":"crossref","first-page":"e0160770","DOI":"10.1371\/journal.pone.0160770","article-title":"CHAIN study. Distribution and outcomes of a phenotype-based approach to guide COPD management: Results from the CHAIN cohort","volume":"11","author":"Cosio","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.arbres.2017.03.018_bib0070","doi-asserted-by":"crossref","first-page":"1700068","DOI":"10.1183\/13993003.00068-2017","article-title":"Algorithm for identification of ACO: Consensus between the Spanish COPD (GesEPOC) and asthma (GEMA) guidelines","volume":"49","author":"Miravitlles","year":"2017","journal-title":"Eur Respir J."},{"key":"10.1016\/j.arbres.2017.03.018_bib0075","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0080","first-page":"7","article-title":"The frequent exacerbator. A new phenotype in COPD?","volume":"6","author":"Soler Catalu\u00f1a","year":"2011","journal-title":"Hot Topics Respir Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0085","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1148\/radiol.11110173","article-title":"Chronic obstructive pulmonary disease exacerbations in the COPDGene study: Associated radiologic phenotypes","volume":"261","author":"Han","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.arbres.2017.03.018_bib0090","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1378\/chest.10-1758","article-title":"Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients","volume":"140","author":"Mart\u00ednez-Garc\u00eda","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2017.03.018_bib0095","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1465-9921-11-58","article-title":"Colour of sputum is a marker of bacterial colonization in COPD","volume":"11","author":"Miravitlles","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.arbres.2017.03.018_bib0100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1183\/09031936.00126808","article-title":"Variability and effects of bronchial colonisation in patients with moderate COPD","volume":"35","author":"Marin","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2017.03.018_bib0105","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.arbres.2013.02.005","article-title":"Tratamiento del tabaquismo en fumadores con enfermedad pulmonar obstructiva cr\u00f3nica","volume":"49","author":"Jim\u00e9nez Ruiz","year":"2013","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2017.03.018_bib0110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.arbres.2015.04.011","article-title":"SEPAR. Guidelines for the evaluation and treatment of muscle dysfunction in patients with chronic obstructive pulmonary disease","volume":"51","author":"Barreiro","year":"2015","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2017.03.018_bib0115","first-page":"CD001495","article-title":"Short-acting beta-2 agonists for stable chronic obstructive pulmonary disease","author":"Sestini","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arbres.2017.03.018_bib0120","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1183\/09031936.97.10040815","article-title":"An evaluation of salmeterol in the treatment of the chronic obstructive pulmonary disease (COPD)","volume":"10","author":"Boyd","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2017.03.018_bib0125","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1183\/09031936.02.00240902","article-title":"Formoterol in patients with chronic obstructive pulmonary disease: A randomized, controlled, 3-month trial","volume":"19","author":"Aalbers","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2017.03.018_bib0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1465-9921-7-147","article-title":"Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo\/usual therapy: Results of a meta-analysis","volume":"7","author":"Stockley","year":"2006","journal-title":"Respir Res"},{"key":"10.1016\/j.arbres.2017.03.018_bib0135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1378\/chest.125.1.249","article-title":"The role of long-acting bronchodilators in the management of stable COPD","volume":"125","author":"Tashkin","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2017.03.018_bib0140","first-page":"237","article-title":"Long-acting \u03b2-adrenoceptor agonists in the management of COPD: Focus on indacaterol","volume":"6","author":"Beier","year":"2011","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2017.03.018_bib0145","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/thorax.58.5.399","article-title":"Health outcomes following six months treatment with once daily tiotropium compared to twice daily salmeterol in patients with COPD","volume":"58","author":"Brusasco","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2017.03.018_bib0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1741-7015-7-2","article-title":"Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: A network meta-analysis","volume":"7","author":"Puhan","year":"2009","journal-title":"BMC Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0155","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus salmeterol for the prevention of exacerbations of COPD","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0160","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","article-title":"Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): A randomised, blinded, parallel-group study","volume":"1","author":"Decramer","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0165","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/COPD.S116719","article-title":"Dual bronchodilation in COPD: Lung function and patient-reported outcomes-a review","volume":"12","author":"Price","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2017.03.018_bib0170","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","article-title":"A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD","volume":"149","author":"Calzetta","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2017.03.018_bib0175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/1753465815624612","article-title":"Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting \u03b22-agonists: A systematic review and network meta-analysis","volume":"10","author":"Schlueter","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.arbres.2017.03.018_bib0180","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12931-016-0425-5","article-title":"Pharmacological strategies to reduce exacerbation risk in COPD: A narrative review","volume":"17","author":"Miravitlles","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.arbres.2017.03.018_bib0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/thoraxjnl-2014-206732","article-title":"Efficacy and safety of long-acting \u03b2-agonist\/long-acting muscarinic antagonist combinations in COPD: A network meta-analysis","volume":"71","author":"Oba","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2017.03.018_bib0190","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2004.10.009","article-title":"Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis","volume":"99","author":"Ram","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0195","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MCP.0000000000000118","article-title":"The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): Opportunities and challenges","volume":"21","author":"Barrecheguren","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0200","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0205","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.00146306","article-title":"Eosinophilic airway inflammation and exacerbations of COPD: A randomised controlled trial","volume":"29","author":"Siva","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2017.03.018_bib0210","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting \u03b2-2 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2017.03.018_bib0215","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1164\/rccm.200904-0492OC","article-title":"Efficacy and tolerability of budesonide\/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease","volume":"180","author":"Welte","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0220","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMoa1008770","article-title":"Tiotropium bromide step-up therapy for adults with uncontrolled asthma","volume":"363","author":"Peters","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0225","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonar disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0230","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0235","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0240","first-page":"CD006829","article-title":"Combined corticosteroid and long-acting beta-agonistin one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease","author":"Nannini","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arbres.2017.03.018_bib0245","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0250","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","article-title":"Blood eosinophils: A biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease","volume":"192","author":"Siddiqui","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0255","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2213-2600(16)30148-5","article-title":"Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: A patient-level meta-analysis","volume":"4","author":"Pavord","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0260","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1001\/archinte.167.19.2047","article-title":"Adverse effects of inhaled corticosteroids in funded and nonfunded studies","volume":"167","author":"Nieto","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0265","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010115.pub2","article-title":"Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease","volume":"3","author":"Kew","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.arbres.2017.03.018_bib0270","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S2213-2600(14)70169-9","article-title":"Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease","volume":"2","author":"Finney","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0275","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0280","article-title":"The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease","volume":"9","author":"Karner","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.arbres.2017.03.018_bib0285","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/thoraxjnl-2014-206670","article-title":"Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol\/fluticasone in patients with COPD: The GLISTEN study, a randomised controlled trial","volume":"70","author":"Frith","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2017.03.018_bib0290","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2017.03.018_bib0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15412555.2015.1034256","article-title":"Efficacy and safety of umeclidinium added to fluticasone propionate\/salmeterol in patients with COPD: Results of two randomized, double-blind studies","volume":"13","author":"Siler","year":"2016","journal-title":"COPD"},{"key":"10.1016\/j.arbres.2017.03.018_bib0300","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","article-title":"Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): A randomized placebo-controlled study","volume":"371","author":"Zheng","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2017.03.018_bib0305","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (bronchitis randomized on NAC cost-utility study, BRONCUS): A randomized placebo-controlled trial","volume":"365","author":"Decramer","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2017.03.018_bib0310","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1378\/chest.13-2784","article-title":"Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD","volume":"146","author":"Tse","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2017.03.018_bib0315","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","article-title":"Twice daily N-acetylcysteine 600mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): A randomised, double-blind placebo-controlled trial","volume":"2","author":"Zheng","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0320","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/COPD.S98333","article-title":"Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation","volume":"11","author":"Santos","year":"2016","journal-title":"Int J Chron Obst Pulm Dis"},{"key":"10.1016\/j.arbres.2017.03.018_bib0325","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: Two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2017.03.018_bib0330","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1183\/09031936.00178710","article-title":"Roflumilast with long-acting b2-agonists for COPD: Influence of exacerbation history","volume":"38","author":"Bateman","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2017.03.018_bib0335","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(14)62410-7","article-title":"Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): A multicentre randomised controlled trial","volume":"385","author":"Martinez","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2017.03.018_bib0340","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201607-1349OC","article-title":"Effect of roflumilast and inhaled corticosteroid\/long-acting \u03b22-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial","volume":"194","author":"Martinez","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0345","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): A randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0350","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pupt.2014.05.002","article-title":"Antibiotic prophylaxis in COPD: Why, when, and for whom?","volume":"32","author":"Miravitlles","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.arbres.2017.03.018_bib0355","doi-asserted-by":"crossref","first-page":"e0121257","DOI":"10.1371\/journal.pone.0121257","article-title":"Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: A meta-analysis","volume":"10","author":"Ni","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.arbres.2017.03.018_bib0360","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","article-title":"Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations","volume":"178","author":"Seemungal","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0365","first-page":"449","article-title":"Long-term a1ithromycin therapy in patients with severe COPD and repeated exacerbations","volume":"6","author":"Pomares","year":"2011","journal-title":"Int J Chron Obst Respir Dis"},{"key":"10.1016\/j.arbres.2017.03.018_bib0370","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0375","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1183\/09031936.00195608","article-title":"Efficacy of moxifloxacin in the treatment of bronchial colonization in COPD","volume":"34","author":"Miravitlles","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2017.03.018_bib0380","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1465-9921-11-10","article-title":"Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial","volume":"11","author":"Sethi","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.arbres.2017.03.018_bib0385","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1056\/NEJMra0800353","article-title":"Infection in the pathogenesis and course of chronic obstructive pulmonary disease","volume":"359","author":"Sethi","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0390","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1164\/rccm.201208-1518OC","article-title":"Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease","volume":"187","author":"Mart\u00ednez-Garc\u00eda","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0395","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1157\/13128330","article-title":"Diagn\u00f3stico y tratamiento de las bronquiectasias","volume":"44","author":"Vendrell","year":"2008","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2017.03.018_bib0400","first-page":"CD001744","article-title":"Domiciliary oxygen for COPD","author":"Cranston","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arbres.2017.03.018_bib0405","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1513\/pats.200708-124ET","article-title":"Oxygen therapy in chronic obstructive pulmonary disease","volume":"5","author":"Kim","year":"2008","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.arbres.2017.03.018_bib0410","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJMoa1604344","article-title":"A Randomized trial of long-term oxygen for COPD with moderate desaturation","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0415","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.arbres.2013.11.025","article-title":"SEPAR. Continuous home oxygen therapy","volume":"50","author":"Ortega Ruiz","year":"2014","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2017.03.018_bib0420","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1378\/chest.06-0180","article-title":"A systematic review of randomized controlled trials examining the short-term benefit of ambulatory oxygen in COPD","volume":"131","author":"Bradley","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2017.03.018_bib0425","doi-asserted-by":"crossref","unstructured":"American Thoracic Society\/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:820-99.","DOI":"10.1164\/rccm.168.7.818"},{"key":"10.1016\/j.arbres.2017.03.018_bib0430","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.arbres.2014.05.008","article-title":"Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic obstructive pulmonary disease: An update","volume":"51","author":"Casas","year":"2015","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2017.03.018_bib0435","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0140-6736(15)60860-1","article-title":"Intravenous augmentation treatment and lung density in severe alpha-1 antitrypsin deficiency (RAPID): A randomised, double-blind, placebo-controlled trial","volume":"386","author":"Chapman","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2017.03.018_bib0440","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1750-1172-8-149","article-title":"Augmentation therapy for alpha-1 antitrypsin deficiency: Towards a personalised approach","volume":"8","author":"Stockley","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.arbres.2017.03.018_bib0445","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.arbres.2016.05.003","article-title":"Spanish registry of patients with alpha-1 antitrypsin deficiency: Database evaluation and population analysis","volume":"53","author":"Lara","year":"2017","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2017.03.018_bib0450","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.rmed.2009.05.018","article-title":"Evaluation of withdrawal of maintenance tiotropium in COPD","volume":"103","author":"Adams","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0455","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.arbres.2014.11.001","article-title":"Correct use of inhaled corticosteroids in chronic obstructive pulmonary disease: A consensus document","volume":"51","author":"Alc\u00e1zar Navarrete","year":"2015","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2017.03.018_bib0460","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00848-2017","article-title":"Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids","author":"Kunz","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2017.03.018_bib0465","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1164\/rccm.200206-512OC","article-title":"Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. The COPE study","volume":"166","author":"Van der Valk","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0470","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1465-9921-15-77","article-title":"Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: A real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)","volume":"15","author":"Rossi","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.arbres.2017.03.018_bib0475","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0480","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2017.03.018_bib0485","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1183\/09031936.00126814","article-title":"INSTEAD: A randomised switch trial of indacaterol versus salmeterol\/fluticasone in moderate COPD","volume":"44","author":"Rossi","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2017.03.018_bib0490","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1465-9921-12-107","article-title":"Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology","volume":"12","author":"Nighat","year":"2011","journal-title":"Respir Res"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289617300844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289617300844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T11:56:26Z","timestamp":1692791786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289617300844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0300289617300844"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2017.03.018","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gu\u00eda espa\u00f1ola de la enfermedad pulmonar obstructiva cr\u00f3nica (GesEPOC) 2017. Tratamiento farmacol\u00f3gico en fase estable","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2017.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}